Table 1.
Characteristics of study groups.
| Parameters | Psoriasis with depression N = 36 | Psoriasis without depression N = 36 | p value |
|---|---|---|---|
| Demographics and clinical history | |||
| Age (years) | 48.7 ± 12.4 | 49.0 ± 12.3 | matched |
| Males, N (%) | 18 (50%) | 18 (50%) | matched |
| Body Mass Index | 30.0 ± 6.6 | 28.5 ± 4.7 | 0.13 |
| Metabolic syndrome, N (%) | 12 (33%) | 5 (14%) | 0.05 |
| Hypertension, N (%) | 13 (36%) | 7 (19%) | 0.11 |
| Type 2 diabetes, N (%) | 3 (8%) | 3 (8%) | 1.00 |
| Hyperlipidemia, N (%) | 17 (47%) | 17 (47%) | 1.00 |
| Current tobacco use, N (%) | 7 (19%) | 7 (19%) | 0.17 |
| Personal history of CAD, N (%) | 2 (6%) | 3 (8%) | 0.64 |
| Family history of CAD, N (%) | 11 (31%) | 15 (42%) | 0.33 |
| Exercise frequency ≥ once weekly, N (%)a | 29 (88%) | 29 (94%) | 0.44 |
| Cardiovascular risk profile | |||
| Systolic BP, mmHg | 125.5 ± 19.0 | 120.2 ± 14.7 | 0.10 |
| Diastolic BP, mmHg | 74.1 ± 10.2 | 71.3 ± 10.3 | 0.13 |
| Total cholesterol, mmol/L | 4.79 ± 1.03 | 4.57 ± 0.99 | 0.18 |
| LDL cholesterol, mmol/L | 2.75 ± 0.84 | 2.56 ± 0.79 | 0.17 |
| HDL cholesterol, mmol/L | 1.35 ± 0.42 | 1.44 ± 0.43 | 0.17 |
| Framingham Risk score [median (IQR)] | 4 (1–6) | 2.5 (1–5) | 0.56 |
| Hs-CRP, nmol/L [median (IQR)] | 20.95 (9.71–41.43) | 22.86 (6.67–62.86) | 0.84 |
| Psoriasis characteristics | |||
| Disease duration, years | 22.3 ± 15.5 | 20.5 ± 15.3 | 0.31 |
| Body surface area affected, % [median (IQR)] | 4.5 (2.8–17.4) | 3.4 (1.7–13.2) | 0.34 |
| PASI score [median (IQR)] | 6.3 (3.2–13.7) | 4.7 (2.8–12.8) | 0.25 |
| Systemic or biologic therapy, N (%) | 12 (33%) | 14 (39%) | 0.62 |
Continuous variables are expressed as Mean ± Standard Deviation unless specified otherwise.
Hs-CRP = High sensitivity C-reactive protein, PASI = Psoriasis Area and Severity Index.
a
N = 33 vs. 31.